148 related articles for article (PubMed ID: 32546235)
1. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma.
Ding X; Yang W; Ren Q; Hu J; Yang S; Han W; Wang J; Wang X; Wang H
J Neuroinflammation; 2020 Jun; 17(1):190. PubMed ID: 32546235
[TBL] [Abstract][Full Text] [Related]
2. IGF-1 alleviates serum IgG-induced neuronal cytolysis through PI3K signaling in children with opsoclonus-myoclonus syndrome and neuroblastoma.
Ding X; Han W; Wang J; Yang W; Chang XF; Zhu ZY; Qin H; Zhang JZ; Wang X; Wang HM
Pediatr Res; 2019 May; 85(6):885-894. PubMed ID: 30718793
[TBL] [Abstract][Full Text] [Related]
3. NK Cell-mediated Neuroblastoma Cell Lysis is Enhanced by IgG From Patients With Pediatric Opsoclonus-Myoclonus Syndrome.
Zar T; Tschernatsch M; Hero B; Lang B; Preissner KT; Blaes F
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e176-e179. PubMed ID: 33060390
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies in childhood opsoclonus-myoclonus syndrome.
Blaes F; Pike MG; Lang B
J Neuroimmunol; 2008 Sep; 201-202():221-6. PubMed ID: 18687475
[TBL] [Abstract][Full Text] [Related]
5. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity.
Raffaghello L; Fuhlhuber V; Bianchi G; Conte M; Blaes F; Gambini C; Pistoia V
J Leukoc Biol; 2013 Jul; 94(1):183-91. PubMed ID: 23610147
[TBL] [Abstract][Full Text] [Related]
6. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology ("Tumor" vs. "No tumor") in a cohort of 356 US children.
Pranzatelli MR; Tate ED; McGee NR
Pediatr Blood Cancer; 2018 Aug; 65(8):e27097. PubMed ID: 29727049
[TBL] [Abstract][Full Text] [Related]
7. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome.
Korfei M; Fühlhuber V; Schmidt-Wöll T; Kaps M; Preissner KT; Blaes F
J Neuroimmunol; 2005 Dec; 170(1-2):150-7. PubMed ID: 16203043
[TBL] [Abstract][Full Text] [Related]
8. Autoantibody-mediated cytotoxicity in paediatric opsoclonus-myoclonus syndrome is dependent on ERK-1/2 phophorylation.
Fühlhuber V; Bick S; Tschernatsch M; Dharmalingam B; Kaps M; Preissner KT; Blaes F
J Neuroimmunol; 2015 Dec; 289():182-6. PubMed ID: 26616889
[TBL] [Abstract][Full Text] [Related]
9. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma.
Raffaghello L; Conte M; De Grandis E; Pistoia V
Eur J Paediatr Neurol; 2009 May; 13(3):219-23. PubMed ID: 18571942
[TBL] [Abstract][Full Text] [Related]
10. The Treatment of Opsoclonus-Myoclonus Syndrome Secondary to Neuroblastic Tumours-Single-Centre Experience and Literature Review.
Mizia-Malarz A; Stolpa W; Sobol-Milejska G
Medicina (Kaunas); 2020 Aug; 56(8):. PubMed ID: 32823831
[No Abstract] [Full Text] [Related]
11. [Comprehensive treatment of neuroblastoma in children associated with opsoclonus-myoclonus-ataxia syndrome].
Zhao W; Sun Q; Xie Y; Hua Y; Xiong H; Jia J; Lu X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):540-3. PubMed ID: 25224062
[TBL] [Abstract][Full Text] [Related]
12. IgG subclass distribution of autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Beck S; Fühlhuber V; Krasenbrink I; Tschernatsch M; Kneifel N; Kirsten A; Jaeger C; Kaps M; Preissner KT; Lang B; Rostasy K; Blaes F
J Neuroimmunol; 2007 Apr; 185(1-2):145-9. PubMed ID: 17324472
[TBL] [Abstract][Full Text] [Related]
13. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Fühlhuber V; Bick S; Kirsten A; Hahn A; Gerriets T; Tschernatsch M; Kaps M; Preissner KT; Blaes F; Altenkämper S
J Neuroimmunol; 2009 May; 210(1-2):87-91. PubMed ID: 19339060
[TBL] [Abstract][Full Text] [Related]
14. The bradykinin-cGMP-PKG pathway augments insulin sensitivity via upregulation of MAPK phosphatase-5 and inhibition of JNK.
Frigolet ME; Thomas G; Beard K; Lu H; Liu L; Fantus IG
Am J Physiol Endocrinol Metab; 2017 Sep; 313(3):E321-E334. PubMed ID: 28679626
[TBL] [Abstract][Full Text] [Related]
15. Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis.
Mancini A; Tantucci M; Mazzocchetti P; de Iure A; Durante V; Macchioni L; Giampà C; Alvino A; Gaetani L; Costa C; Tozzi A; Calabresi P; Di Filippo M
Neurobiol Dis; 2018 May; 113():97-108. PubMed ID: 29325869
[TBL] [Abstract][Full Text] [Related]
16. Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment.
Blaes F; Dharmalingam B
Expert Rev Neurother; 2016 Jun; 16(6):641-8. PubMed ID: 27095464
[TBL] [Abstract][Full Text] [Related]
17. Regulation of cGMP-dependent protein kinase expression by soluble guanylyl cyclase in vascular smooth muscle cells.
Browner NC; Dey NB; Bloch KD; Lincoln TM
J Biol Chem; 2004 Nov; 279(45):46631-6. PubMed ID: 15337747
[TBL] [Abstract][Full Text] [Related]
18. The NO/sGC/PKG signaling pathway in the NAc shell is necessary for the acquisition of morphine-induced place preference.
Shen F; Wang N; Qi C; Li YJ; Cui CL
Behav Neurosci; 2014 Aug; 128(4):446-59. PubMed ID: 25046820
[TBL] [Abstract][Full Text] [Related]
19. Embryonic motor neuron dendrite growth is stunted by inhibition of nitric oxide-dependent activation of soluble guanylyl cyclase and protein kinase G.
Xiong G; Mojsilovic-Petrovic J; Pérez CA; Kalb RG
Eur J Neurosci; 2007 Apr; 25(7):1987-97. PubMed ID: 17439487
[TBL] [Abstract][Full Text] [Related]
20. Opsoclonus-myoclonus Syndrome with Neuroblastoma in Children and their Anaesthetic Management.
Gupta A; Kundal R; Pandey M
J Coll Physicians Surg Pak; 2022 Aug; 32(8):1086-1088. PubMed ID: 35932142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
